U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
Dalbavancin is a second-generation lipoglycopeptide antibiotic that was designed to improve on the natural glycopeptides currently available, such as vancomycin and teicoplanin. Modifications from these older glycoprotein classes allowed a similar mechanism of action with increased activity and once weekly dosing. Its use is indicated for the treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by the following gram-positive microorganisms: Staphylococcus aureus (including methicillin-susceptible and methicillin-resistant strains), S. pyogenes, S. agalactiae, and S. anginosus group (including S. anginosus, S. intermedius, and S. constellatus). Under the brand name DALVANCE Dalbavancin is indicated for acute bacterial skin and skin structure infections (ABSSSI) caused by designated susceptible strains of Gram-positive microorganisms. The bactericidal action of dalbavancin results primarily from inhibition of cell-wall biosynthesis. Specifically, dalbavancin prevents incorporation of N-acetylmuramic acid (NAM)- and N-acetylglucosamine (NAG)-peptide subunits from being incorporated into the peptidoglycan matrix; which forms the major structural component of Gram-positive cell walls. The large hydrophilic molecule is able to form hydrogen bond interactions with the terminal D-alanyl-D-alanine moieties of the NAM/NAG-peptides, which is normally a five-point interaction. Binding of dalbavancin to the D-Ala-D-Ala prevents the incorporation of the NAM/NAG-peptide subunits into the peptidoglycan matrix. In addition, dalbavancin alters bacterial-cell-membrane permeability and RNA synthesis.

CNS Activity

Curator's Comment:: Dalbavancin was widely distributed into tissues, but did not cross the blood brain barrier.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Curative
DALVANCE

Approved Use

INDICATION AND USAGE DALVANCE is indicated for acute bacterial skin and skin structure infections (ABSSSI) caused by designated susceptible strains of Gram-positive microorganisms. (1.1) To reduce the development of drug-resistant bacteria and maintain the effectiveness of DALVANCE and other antibacterial drugs, DALVANCE should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. (1.2) 1.1 Acute Bacterial Skin and Skin Structure Infections DALVANCE® (dalbavancin) for injection is indicated for the treatment of adult patients with acute bacterial skin and skin structure infections (ABSSSI), caused by susceptible isolates of the following Gram-positive microorganisms: Staphylococcus aureus (including methicillin-susceptible and methicillin-resistant strains), Streptococcus pyogenes, Streptococcus agalactiae, Streptococcus dysgalactiae, Streptococcus anginosus group (including S. anginosus, S. intermedius, S. constellatus) and Enterococcus faecalis (vancomycin susceptible strains). 1.2 Usage To reduce the development of drug-resistant bacteria and maintain the effectiveness of DALVANCE and other antibacterial agents, DALVANCE should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

Launch Date

1.40080316E12
PubMed

PubMed

TitleDatePubMed
New lipoglycopeptides: a comparative review of dalbavancin, oritavancin and telavancin.
2010 May 7
Impact of Glycopeptide Resistance in Staphylococcus aureus on the Dalbavancin In Vivo Pharmacodynamic Target.
2015 Dec
Evaluation of Antibiotics Active against Methicillin-Resistant Staphylococcus aureus Based on Activity in an Established Biofilm.
2016 Oct
Once-Daily Treatments for Methicillin-Susceptible Staphylococcus aureus Bacteremia: Are They Good Enough?
2017 Sep 23
Patents

Sample Use Guides

1. Two-dose regimen: 1000 mg followed one week later by 500 mg (2.1) 2. Dosage adjustment for patients with creatinine clearance less than 30 mL/min and not receiving regularly scheduled hemodialysis: 750 mg followed one week later by 375 mg (2.2) 3. Administer by intravenous infusion over 30 minutes (2.3)
Route of Administration: Intravenous
Nearly all (99.8%) multidrug-resistant methicillin-resistant S. aureus isolates were inhibited by dalbavancin at ≤0.12 ug/ml (MIC50/90, 0.06/0.06 ug/ml).
Substance Class Mixture
Created
by admin
on Sat Jun 26 21:05:04 UTC 2021
Edited
by admin
on Sat Jun 26 21:05:04 UTC 2021
Record UNII
33WDQ7T81E
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
DALBAVANCIN HYDROCHLORIDE
DASH   WHO-DD  
Common Name English
DALBAVANCIN HYDROCHLORIDE (1:1.6)
Common Name English
DALBAVANCIN HYDROCHLORIDE [ORANGE BOOK]
Common Name English
DALBAVANCIN HYDROCHLORIDE (5:8)
Common Name English
DALVANCE
Brand Name English
DALBAVANCIN HYDROCHLORIDE [WHO-DD]
Common Name English
Code System Code Type Description
DRUG BANK
DBSALT001105
Created by admin on Sat Jun 26 21:05:04 UTC 2021 , Edited by admin on Sat Jun 26 21:05:04 UTC 2021
PRIMARY
ChEMBL
CHEMBL3301669
Created by admin on Sat Jun 26 21:05:04 UTC 2021 , Edited by admin on Sat Jun 26 21:05:04 UTC 2021
PRIMARY
FDA UNII
33WDQ7T81E
Created by admin on Sat Jun 26 21:05:04 UTC 2021 , Edited by admin on Sat Jun 26 21:05:04 UTC 2021
PRIMARY
EVMPD
SUB130539
Created by admin on Sat Jun 26 21:05:04 UTC 2021 , Edited by admin on Sat Jun 26 21:05:04 UTC 2021
PRIMARY
RXCUI
1541465
Created by admin on Sat Jun 26 21:05:04 UTC 2021 , Edited by admin on Sat Jun 26 21:05:04 UTC 2021
PRIMARY RxNorm
Related Record Type Details
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY
Definition References